Eurostars Granted Project “A novel modified natural killer (NK) cell immunotherapy for the treatment of solid tumours” – MODIFY-NK

17 May Eurostars Granted Project “A novel modified natural killer (NK) cell immunotherapy for the treatment of solid tumours” – MODIFY-NK

Eurostars 2018

 

Eurostars, a European joint programme, co-funded from the national budgets of several EUREKA countries and by the European Union through Horizon 2020 has awarded, through a highly-competitive selection process, the Project “A novel modified natural killer (NK) cell immunotherapy for the treatment of solid tumours” – MODIFY-NK.

The consortium composed of Glycostem Therapeutics BV (The Netherlands), YUMAB GmbH (Germany), Explicyte (France) and OZ Biosciences SAS (France) will deliver a novel cell-based therapy to treat solid tumours with chimeric antigen receptors (CAR) expressing allogeneic (i.e. from a patient independent donor) natural killer (NK) cells. These CARs strongly improve solid tumour targeting and killing potential. The efficacy of this clinical grade CAR-NK cell product will be validated in a preclinical solid tumour model and the therapy will be ready for clinical studies within 24 months after completion of this project.

The total reward amounts to €3,626,860.00 for the 3-year programme.

“Combining the key expertise of the consortium members will bring innovative insights in the active field of immuno-oncology research. We are looking forward to initiating this strategic project taking advantage of motivating technical challenges to reach attractive therapeutic outcomes” said Alban Bessede, CEO of Explicyte.

 

Download the complete press release document.

contact us

 I agree with the use of my personal data for further communications according to explicyte privacy policy

Eurostars granted project “A novel modified natural killer (NK) cell immunotherapy for the treatment of solid tumours” – MODIFY-NK.